Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension | Zendy

Neely Ivgy-May | Zendy; Goeran Hajak | Zendy; Gonnie van Osta | Zendy; Sabine Braat | Zendy; Qing Chang | Zendy; Thomas Roth | Zendy

Open Access

Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension

Author(s) -

Neely Ivgy-May,

Goeran Hajak,

Gonnie van Osta,

Sabine Braat,

Qing Chang,

Thomas Roth

Publication year - 2020

Publication title -

journal of clinical sleep medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.529

H-Index - 92

eISSN - 1550-9397

pISSN - 1550-9389

DOI - 10.5664/jcsm.8526

Subject(s) - tolerability , placebo , chronic insomnia , primary insomnia , medicine , insomnia , randomized controlled trial , physical therapy , psychology , psychiatry , adverse effect , sleep disorder , alternative medicine , pathology

Esmirtazapine (1.5-4.5 mg) has demonstrated short-term sleep-promoting effects in nonelderly outpatients with chronic insomnia. This phase 3, randomized, double-blind study (NCT00631657) and its open-label extension (NCT00750919) investigated efficacy and safety of long-term esmirtazapine treatment in adult outpatients with chronic insomnia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research